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Abstract
Background: The prevalence of infections with Mycobacterium tuberculosis (MTb) and nontuberculous
mycobacteria (NTM) species in HIV-infected patients in Mexico is unknown. The aims of this study were to
determine the frequency of MTb and NTM species in HIV-infected patients from Mexico City, to evaluate the
genotypic diversity of the Mycobacterium tuberculosis complex strains, to determine their drug resistance profiles by
colorimetric microplate Alamar Blue assay (MABA), and finally, to detect mutations present in katG, rpoB and inhA
genes, resulting in isoniazid (INH) and rifampin (RIF) resistance.
Results: Of the 67 mycobacterial strains isolated, 48 were identified as MTb, 9 as M. bovis,9a sM. avium and 1 as
M. intracellulare.I S 6110-RFLP of 48 MTb strains showed 27 profiles. Spoligotyping of the 48 MTb strains yielded 21
patterns, and 9 M. bovis strains produced 7 patterns. Eleven new spoligotypes patterns were found. A total of 40
patterns were produced from the 48 MTb strains when MIRU-VNTR was performed. Nineteen (39.6%) MTb strains
were resistant to one or more drugs. One (2.1%) multidrug-resistant (MDR) strain was identified. A novel mutation
was identified in a RIF-resistant strain, GAG ® TCG (Glu ® Ser) at codon 469 of rpoB gene.
Conclusions: This is the first molecular analysis of mycobacteria isolated from HIV-infected patients in Mexico,
which describe the prevalence of different mycobacterial species in this population. A high genetic diversity of
MTb strains was identified. New spoligotypes and MIRU-VNTR patterns as well as a novel mutation associated to
RIF-resistance were found. This information will facilitate the tracking of different mycobacterial species in HIV-
infected individuals, and monitoring the spread of these microorganisms, leading to more appropriate measures
for tuberculosis control.
Background
Tuberculosis (TB) remains the most common opportu-
nistic infection for people living with human immuno-
deficiency virus (HIV), and a leading cause of death in
low and middle-income countries [1]. The number of
new TB cases has tripled in countries where the inci-
dence of HIV is high in the last two decades [2]. At
least one-third of the 33.2 million people living with
HIV worldwide are infected with TB and have up to
15% risk of developing TB every year, compared to
those without HIV who have a 10% risk over their life-
time [3]. In Mexico, HIV-infected patients account for
1.0% of new TB cases [4]. In other developing countries,
it has been reported that in HIV-infected patients,
Mycobacterium tuberculosis (MTb) is not the only
mycobacteria that causes disease, nontuberculous myco-
bacteria (NTM) have also been found in such patients
[5,6]. In Mexico identification of mycobacterial species
is generally based on clinical features, sometimes with
the help of a positive acid-fast stain [7]. * Correspondence: jgonzal1212@hotmail.com
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molecular typing of strains has become a valuable tool
in TB epidemiological studies allowing investigators to
track epidemics, detect new outbreaks, and achieve bet-
ter knowledge of strain movement distinguishing
between reinfection and relapse [8]. IS6110 restriction
fragment length polymorphism (RFLP) typing of MTb
has been used extensively in studies of TB transmission
and is one of the most widely applied and standardized
molecular typing methods [9,10]. Spacer oligonucleotide
typing (spoligotyping) is another molecular genotyping
technique; it is fast, robust, reliable, easy to perform,
and cost-effective [11]. Spoligotyping is based on the
analysis of the direct repeat (DR) loci, which are com-
prised of directly repeated sequences interspersed with
non-repetitive spacer DNA [11]. This rapid PCR-based
method allows the classification of strains into spoligo-
type families based on the presence or absence of spacer
regions [12,13]. The most promising PCR-based meth-
ods are based on the analysis of multiple loci containing
variable numbers of tandem repeats (VNTR) of different
families of interspersed genetic elements, collectively
called mycobacterial interspersed repetitive units
(MIRU) [14,15]. Currently, the most commonly used
version of this method (designated MIRU-VNTR) is
based on the analysis of 12 loci [16]. Some authors have
found that this method shows a discriminatory power
equivalent to that of RFLP and for this reason it has
been considered an alternative method to IS6110-RFLP
for epidemiological studies [14,16,17]. One of the most
alarming trends concerning TB is the emergence of
drug-resistant MTb strains, which have become a world-
wide health care problem [18]. The number of multi-
drug-resistant strains of MTb (MDR-TB), defined as
r e s i s t a n tt oa tl e a s ti s o n i a z i d( I N H )a n dr i f a m p i n( R I F ) ,
has been steadily increasing over the years, and several
outbreaks have been reported [19,20]. The development
of resistance to these two drugs reduces the efficacy of
standard antituberculosis treatment to 77%. For this rea-
son it is important to identify resistant strains as soon
as possible to permit adjustments in treatment and
minimize transmission of drug-resistant strains. Muta-
tions in the catalase peroxidase gene (katG) [21,22] and
in a gene encoding the enoyl acyl carrier protein reduc-
tase (inhA) [23] have been found to account for 60 to
70% and 10 to 15% of INH-resistant MTb strains,
respectively [24]. Mutations resulting in a single amino
acid change within the 81-bp core region of the RNA
polymerase b-subunit (rpoB) gene are found in 96% of
RIF-resistant MTb strains [25].
The aims of this study were to determine the preva-
lence of mycobacterial species in HIV-infected patients
from Mexico City and surrounding areas, to evaluate
the genotypic diversity of the Mycobacterium
tuberculosis complex (MTC) strains using IS6110 RFLP,
spoligotyping and MIRU-VNTR, to determine their drug
resistance profiles, and to detect mutations present in
katG, inhAa n drpoB genes that lead to the selection of
INH- and RIF-resistant strains.
Results
Mycobacteria prevalence in HIV-infected patients
In this study we characterized 67 mycobacterial strains
isolated from HIV-infected patients, 85% of strains
belonged to the MTC; 48 (71.6%) were MTb, 9 (13.4%)
M. bovis, and the remaining 15% were NTM: 9 (13.4%)
corresponded to M. avium and 1 (1.5%) to M. intracel-
lulare. Thirty MTb strains (62.5%) were isolated from
pulmonary specimens, while 8 of 9 M. avium strains
(89%) were isolated from extrapulmonary specimens.
Thirteen patients presented more than one site of infec-
tion (see Table 1).
RFLP analysis
RFLP analysis of all MTb strains was performed using
IS6110 as probe. The IS6110 fingerprint patterns gener-
ated were highly variable. The number of IS6110 copies
per strain varied from 0 to 14. Of IS6110 fingerprint
patterns observed, 19 (39.6%) were unique, indicating
epidemiological independence (Figure 1), and 10 strains
(20.8%) lacked IS6110 (zero copy number). These pat-
terns (zero IS6110 bands) were confirmed by performing
a second RFLP analysis where MTb H37Rv was included
as control strain. Additionally, 19 strains (39.6%) were
clustered in 8 groups consisting of 2 to 3 strains with
identical IS6110 RFLP patterns, presumably representing
cases of recent transmission, and 16 (33.3%) strains pre-
sented IS6110 RFLP patterns with five bands or fewer.
Spoligotyping
To determine lineage, the 57 strains (48 MTb and 9
M. bovis) from the MTC were spoligotyped and binary
outcomes were compared with the shared type (ST)
number and lineages and sublineages reported by Bru-
dey et al [26]. Spoligotype analysis of 48 MTb strains
yielded 21 patterns (Figure 1). Thirty-nine MTb strains
(81.3%) were grouped into 12 clusters (2 to 10 strains
per cluster) while 9 strains showed unique patterns.
Thirty-four MTb strains showed 12 spoligotyping pat-
terns that matched with: Shared-type (ST) number 2
(lineage name H2; n = 1), ST42 (LAM9; n = 10), ST47
(H1; n = 2), ST50 (H3; n = 2), ST53 (T1; n = 5), ST119
(X1; n = 3), ST137 (X2; n = 2), ST274 (U; n = 1),
S T 5 0 8( T 1 ;n=4 ) ,S T 7 3 2( T 1 ;n=2 ) ,S T 9 4 8( H 3 ;
n = 1), and ST1626 (T1; n = 1). A further 14 MTb
s t r a i n ss h o w e d9p a t t e r n st h a td i dn oe x i s ti nt h e
SpolDB4.0 database (see question marks, Figure 1). Spo-
ligotyping allows discrimination of MTb strains with
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Page 2 of 12Table 1 Genomic patterns of mycobacterial strains isolated from different clinical samples of the same patient
Patient Strain
code
Clinical sample Mycobacterial
specie
Spoligotyping Share type (ST)
number
RFLP
cluster
MIRU-VNTR (code
number)
1 IPN 24 Pleural effusion MTb ST42 16 23’3216153321
IPN 25 urine MTb ST42 16 225225153323
2 IPN 29 Urine MTb ST732 12 220326153322
IPN 31 Sputum MTb ST732 12 223326153322
3 IPN 64 Urine MTb ST119 9 223224153323
IPN 67 Bronchoalveolar lavage
fluid
MTb ST119 10 23’3226133321
4 IPN 69 Urine MTb ?
h 23 332226153322
IPN 70 Bronchoalveolar lavage
fluid
MTb ?
h 23 225223153322
5 IPN 74 Urine MTb ST50 1 223225123322
IPN 75 Sputum MTb ST50 1 224325153324
6 IPN 10 Bone marrow MTb ST42 15 23’3226133321
IPN 11 Sputum MTb ST42 15 225225153323
IPN 12 Bronchoalveolar lavage
fluid
MTb ST42 15 225226143323
7 IPN 15 Pleural effusion MTb ?
b ● 223326133321
IPN 16 Sputum MTb ?
b ● 223326133321
IPN 17 Gastric fluid MTb ?
b ● 223226133322
8 IPN 85 Bone marrow MTb ST508 8 220225150020
IPN 86 Bronchoalveolar lavage
fluid
MTb ST508 8 223225153321
IPN 87 Sputum MTb ST508 8 220005153320
9 IPN 43 Pleural effusion M. bovis ST1306 ND 232224253322
IPN 99 Lymph node M. bovis ST1625 ND 232224253322
10 IPN 56 Urine M. bovis ST409 ND 232224153323
IPN 57 Sputum M. bovis ST409 ND 222224053320
IPN 58 Cerebrospinal fluid M. bovis ?
i ND 232224253322
11 IPN 46 Cerebrospinal fluid M. bovis ST683 ND 232224152320
IPN 47 Cerebrospinal fluid M. bovis ST479 ND 332224153322
IPN 48 Gastric fluid M. bovis ?
j ND 232225153322
IPN 49 Sputum M. bovis ST479 ND 332225153322
12 IPN 1 Bone marrow M. avium ND ND ND
IPN 3 Gastric fluid M. avium ND ND ND
13 IPN 41 Bone marrow M. avium ND ND ND
IPN 60 Lymph node M. avium ND ND ND
MTb, M. tuberculosis. ND, No determined, ?
b, Spoligotype octal, 777743677760771, ?
h, Spoligotype octal 777777660000131, ?
i, Spoligotype octal
264063776776600, ?
j, Spoligotype octal 677767777777600, ●, M. tuberculosis strains with zero-copy-numbers of IS6110.
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Page 3 of 12Figure 1 Spoligotyping, IS6110 RFLP and MIRU-VNTR patterns of M. tuberculosis (MTb) and M. bovis strains isolated from HIV-infected
patients. The dendrogram is based on spoligotyping patterns. A) Spoligotyping patterns (binary representation); B) Shared-type (ST) number;
C) IS6110-RFLP patterns; D) RFLP cluster; E)12 MIRU-VNTR patterns; F) Strain code. ?, new patterns of spoligotypes; ?
a, Spoligotype octal
777577777720771, ?
b, Spoligotype octal 777743677760771, ?
c, Spoligotype octal 777747677760771, ?
d, Spoligotype octal 777777705720771,
?
e, Spoligotype octal 777777705720661, ?
f, Spoligotype octal 677767604760621, ?
g, Spoligotype octal 677777477413661, ?
h, Spoligotype octal
777777660000131, ?
i, Spoligotype octal 264063776776600, ?
j, Spoligotype octal 677767777777600, ?
k, Spoligotype octal 775346770000000;
●, M. tuberculosis strains with zero-copy-numbers of IS6110; H37Rv, M. tuberculosis H37Rv; BGC, M. bovis BCG; ♦, M. bovis strains. *, Reference
strains used as controls. ■, INH-resistant MTb strains
Lopez-Alvarez et al. BMC Microbiology 2010, 10:82
http://www.biomedcentral.com/1471-2180/10/82
Page 4 of 12low-copy-numbers of IS6110 (see Figure 1; for example,
strains MEX-IPN 15, MEX-IPN 16, MEX-IPN17 and
MEX-IPN 44). Nine M. bovis strains yielded 7 spoligo-
typing patterns; 5 unique patterns and 2 clusters with 2
strains in each one (Figure 1). The M. bovis spoligotyp-
ing patterns matched with ST409 (BOVIS2; n = 2),
S T 4 7 9( B O V I S 3 ;n=2 ) ,S T 6 8 3( B O V I S 2 ;n=1 ) ,
ST1306 (BOV; n = 1), ST1625 (BOVIS2; n = 1), and 2
new patterns were identified (Figure 1).
MIRU-VNTR patterns
Clustering of MIRU-VNTR patterns by the UPGMA
method showed a greater diversity of patterns in the
mycobacterial strains studied. A total of 40 patterns
were produced from 48 MTb strains, 5 clusters were
identified (2 clusters with 4 and 3 strains, respectively,
and 3 clusters with 2 strains in each). The remaining 35
strains showed unique patterns. Nine M. bovis strains
produced a total of 7 patterns (Figure 1), 1 cluster was
identified with 3 strains, while 6 strains presented
unique patterns.
Genomic diversity of MTb isolates
The discriminatory power of MIRU-VNTR typing was
c o m p a r e dt ot h a to fI S 6110 RFLP and spoligotyping by
analyzing only MTb strains. Overall, MIRU-VNTR typ-
ing discriminated 40 different patterns (Figure 1); in
comparison, only 27 different patterns were obtained
with IS6110 RFLP and 21 patterns were obtained with
spoligotyping. MIRU-VNTR typing performed even bet-
ter than a combination of spoligotyping and IS6110
RFLP, which discriminated 36 patterns. The maximal
discrimination was apparent l ya c h i e v e db yc o m b i n i n g
MIRU-VNTR and IS6110 RFLP typing, resulting in 46
patterns.
Spoligotypes could often be distinguished by MIRU-
VNTR typing; for instance, the single ST42 spoligotype
corresponded to 9 distinctM I R U - V N T Rg e n o t y p e s
(Figure 1). By contrast, just three of the MIRU-VNTR pat-
terns (225225153323, 23’3226133321 and 225315153323)
were distinguished by spoligotyping.
Genomic patterns of mycobacterial strains isolated from
the same patient
Identical spoligotyping and RFLP patterns were found
among each set of strains in 7 out of 8 patients that
were infected with more than one MTb strain (Table 1;
patients 1, 2, 4-8). Only one patient (patient 3) had two
strains that differed in both, RFLP and MIRU-VNTR
typings, suggesting that, this particular patient was
infected with two different strains of MTb. Regarding
M. bovis strains, patients 9, 10 and 11 (Table 1) were
infected with 2, 3 and 4 different strains according to
their spoligotyping and MIRU-VNTR typing. Each of
patients 12 and 13 were infected with two M. avium
strains; but whether these are different strains remains
to be determined.
Phenotypic drug resistance testing
A total of 57 strains (48 MTb and 9 M. bovis) were sub-
jected to colorimetric microplate Alamar Blue assay
(MABA). Testing indicated that 9 M. bovis strains were
susceptible to the 4 drugs tested, while 19 (39.6%) MTb
strains showed resistance to one or more drugs (Table
2). Only one (2.1%) MTb strain was MDR, and 18 (95%)
of them were resistant to STR. As none of M. bovis
strains showed resistance to the 4 antibiotics tested, no
further characterization was carried out on them. No
phenotypic or genotypic drug resistance tests were car-
ried out in NTM.
Genotypic drug resistance testing
Mutations in katG, inhA and rpoB associated with resis-
tance were found in 5 (10.4%) MTb strains. Our study
shows that strains isolated from HIV-infected patients
not only have mutations in regions of genes previously
shown to be involved in drug resistance, but also have
mutations that have not been previously reported. The
nucleotide and amino acid changes identified in the
drug resistant strains are shown in the Table 3. Among
the INH-resistant strains, 3 strains had a mutation
Table 2 Drug resistance of M. tuberculosis (MTb) strains
isolated from HIV-infected patients
Drug resistance
a No. (%) of strains
M. bovis
Total strains
9 (100)
Non-resistant strains 9 (100)
M. tuberculosis
Total strains
48 (100)
Non-resistant strains 29 (60.4)
Strains resistant to one or more drugs 19 (39.6)
Resistance to one drug only
STR 12 (25)
EMB 1 (2.1)
Resistance to more than one drug
INH, STR 2 (4.2)
RIF, STR 1 (2.1)
STR, EMB 1 (2.1)
INH, STR, EMB 1 (2.1)
INH, RIF, STR, EMB 1 (2.1)
aINH, isoniazid; RIF, rifampin; STR, streptomycin; EMB, ethambutol.
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Page 5 of 12AGC ® ACC at codon 315 of katGg e n e( S e r® Thr),
corresponding to the most common mutation found in
INH-resistant strains [27,28]. The MDR strain had sub-
stitution mutations AGC ® ACC (Ser ® Thr) at codon
315 of katGa n dT C G® TTG, at codon 531 of the
rpoB gene, resulting in a predicted amino acid change of
Ser ® Leu. One RIF-resistant isolate had a mutation
GAG ® TCG (Glu ® Ser) at codon 469 of the rpoB
gene that has not been described previously. There was
no correlation between the mutations and genotyping
patterns of different strains in this study, i.e. the INH-
resistant MTb strains (IPN7, IPN12, IPN28 and IPN32)
had the same substitution mutation AGC ® ACC (Ser
® Thr) at codon 315 of the katG gene, however they
differ in the spoligotyping, IS6110 RFLP and MIRU-
VNTR patterns (see Figure 1 and Table 3).
Discussion
In this study we analyzed 67 mycobacterial strains iso-
lated from HIV-infected patients attending different hos-
pitals in Mexico City. Diagnosis of mycobacterial
infection in Mexico is based on clinical symptoms with
Ziehl-Neelsen staining (AFB) being the only laboratory
confirmation of infection currently in use. Many patients
are treated for MTb purely on the basis of a positive
AFB test and in most cases strains are not tested for
NTM due to the procedure for this characterization
being lengthy and expensive. The incomplete identifica-
tion of mycobacterial species producing infection can
have serious consequences, resulting in longer hospitali-
zation times, increased risk of nosocomial infections and
selection of MDR strains. Delayed diagnosis is a key fac-
tor contributing to the unnecessary deaths of many peo-
ple living with HIV. More importantly proper
identification of mycobacterial species causing infection
leads to more appropriate antimicrobial treatment [29].
In agreement with results from a previous study by
Molina-Gamboa et al [7], we found thatMTb was the
most prevalent mycobacterial species identified in HIV-
patient samples investigated in this study. Of the 9.27
million patients globally-infected with MTb in 2007, an
estimated 1.37 million (14.8%) were HIV positive [30].
At least one-third of the 33.2 million people living with
HIV worldwide are infected with TB and individuals
infected with HIV are 20 to 30 times more likely to
develop TB than those without the virus [2]. Although
MTb is the most important etiological agent of TB, M.
bovis, can also be considered a potential cause of human
cases, especially in developing countries where control
measures for bovine TB in cattle and/or milk dairy pro-
ducts are not always satisfactory [31]. With the advent
of HIV, bovine TB represents an additional risk for
HIV-infected patients. Importantly, pulmonary or extra-
pulmonary TB caused by M. bovis,m a yb eu n d e r e s t i -
mated due to the fact that the resulting infection is
clinically indistinguishable from that caused by MTb. In
this study 13.4% of strains isolated were identified as
M. bovis. Our results are consistent with those reported
by Cicero et al [32], who also identified M. bovis in
extrapulmonary samples (13.75%) from HIV-infected
patients in Mexico. In an earlier study, Molina-Gamboa
et al [7] identified M. bovis in 4.6% of patients with HIV
using only biochemical tests.
Although in the past two decades NTM infections
have been regarded as a growing concern, mainly as a
result of the AIDS epidemic, these microorganisms were
first recognized in the 1950s when the prevalence of TB
fell after the introduction of antimycobacterial therapy
[33]. NTM produce both pulmonary and extrapulmon-
ary disease in both immunocompetent and immuno-
compromised subjects [33]. In this study, 15% of
isolated mycobacterial strains were NTM. The mycobac-
teria identified in this study belonged to the MAC com-
plex: M. avium-M. intracellulare, findings which are
consistent with those reported by Molina-Gamboa et al
[7], who identified these mycobacteria as the second
most prevalent acid-fast bacilli isolated from HIV-
infected patients in Mexico. Countries with limited
resources like Mexico do not identify mycobacteria by
culture and molecular techniques and because of this
infections caused by NTM are under diagnosed or mis-
diagnosed. This study emphasizes the need for molecu-
lar identification of NTM in HIV-infected patients.
RFLP analysis based on IS6110 insertion is used to
define clusters of MTb strains with identical DNA fin-
gerprints. However, to the best of our knowledge, there
have been no studies in Mexico that have used IS6110
RFLP analysis to characterize MTb strains isolated from
HIV-infected patients. Using this method we showed
wide genetic variability in Mexican strains (27 patterns
from 48 MTb strains). Our results are similar to those
reported in countries like Tanzania where Yang et al
Table 3 Mutations found in M. tuberculosis (MTb) strains
resistant to rifampin and isoniazid
Rifampin
Mutated
rpoB codon
Specific
mutation
Strain
n
MIC
(μg/ml)
531 TCG ® TTG (Ser ® Leu)
a 1> 2
469 GAG ® TCG (Glu ® Ser)
b 1 0.5
Isoniazid
Mutated
katG codon
Specific
mutation
Strain
n
MIC
(μg/ml)
315 AGC ® ACC (Ser ® Thr)
a 3> 1
315 AGC ® ACC (Ser ® Thr) 1 1
aMutations found in the MDR M. tuberculosis strain
bMutation not described previously
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Page 6 of 12[34] obtained 60 patterns from 68 MTb clinical strains
and In Switzerland, where Strässle et al [35] identified
40 different patterns from 52 MTb strains isolated from
HIV-infected patients. Our findings differ from reports
of the numbers of different MTb strains isolated from
non-HIV population within endemic regions, where it
has been shown that variability in IS6110 patterns is low
[36]. The contrasting wide diversity of MTb strains
from HIV-infected patients found in Tanzania, Switzer-
land and now in Mexico, might be explained by these
patients having a deficient immune system, and thus
providing the perfect habitat for the development of
infection regardless of mycobacterial virulence [34].
I nt h ep r e s e n ts t u d yw ei d e n t i f i e d1 6M T bs t r a i n s
(33.3%) with five or fewer copies of IS6110;1 0o ft h e s e
(20.8%) lacked IS6110.M T bs t r a i n sw i t hl o wI S 6110
copy number have been more frequently isolated from
Asian patients than from European patients. For exam-
ple, 56% of the strains collected from India and 29 to
37.5% of the strains collected from Vietnam, Thailand
and Malaysia contained five or fewer IS6110 elements
[37,38], whereas the frequencies of low-copy-number
strains in Denmark and France were 11% and 8%,
respectively [39,40]. In the United States, analysis of
strains from Texas, California, and Colorado reported
25% containing fewer than six IS6110 copies [41]. The
reports of the incidence of strains with low copy num-
ber insertions from the United States are closer to the
incidence of the Mexican strains isolated in our work.
In this study, 48 MTb strains produced 21 spoligotyp-
ing patterns, while 9 M. bovis produced just 7 patterns.
Quitugua et al [42] had reported the spoligotype
777776777760601 (ST137) in 63 patients from Texas,
this pattern was identified in 2 strains in our study.
Likewise, the octal 777776777760771 (ST119) which was
identified in 89 patients who live on the border of Mex-
ico (Tamaulipas) and United States (Texas), was identi-
fied in 3 strains in this study. Other octals found by
Quitugua et al and also in our work, were
777777777760771 (ST53) and 777777607760771 (ST42),
confirming that there are some strains of MTb circulat-
ing between Mexico and United States. The spoligotypes
ST42, ST47, ST50 and ST53 identified in this study,
have been found in others countries including Brazil,
South Africa and Poland [43-45], suggesting that these
strains might be circulating worldwide. Furthermore, the
ST53 spoligotype has also been isolated from Egyptian
mummies [46]; this spoligotype is one of the most com-
mon patterns and, according to a hypothesis about the
evolution of MTb strains by loss of DRs [47], close to
the origin of development of mycobacterial diversity.
The ST683 spoligotype found in M. bovis strains iso-
lated in this study has also been found in cattle from
Juarez City and Chihuahua (Mexico) [48] and has been
frequently isolated from cattle in Australia, Argentina,
England, France and Ireland [49-53]. The pattern of
transmission of M. bovis to HIV-infected patients is still
under study; however, the identification of the same
spoligotype patterns in both cattle and HIV-infected
patients indicates that, as is generally accepted, ingestion
of contaminated milk or dairy products is the most
probable origin of infection [31].
This study is the first in Mexico where genetic diver-
sity of mycobacterial strains has been evaluated using
MIRU-VNTR. The 48 MTb strains investigated in this
report produced 40 distinct patterns by MIRU-VNTR
while 9 M. bovis strains produced 7. Analysis of these
results showed that most of these patterns were unique,
consistent with other studies conducted in Singapore
and Belgium, where there was wide variability in MTb
strains [54,55]. As expected, most of clusters based on
spoligotyping or low IS6110 copy number fingerprinting
could be distinguished by MIRU-VNTR. Additionally, in
strains isolated from HIV-infected patients, 4 MIRU
(4, 20, 23 and 31) were showed to have a different pat-
tern compared with those occurring in the population
without HIV; MIRU 4 and 31 in strains isolated from
HIV-infected patients presented with low polymorphism,
while those identified from individuals without HIV
have a high polymorphism. By contrast, MIRU 20 and
23 of strains from HIV-infected patients have a high
polymorphism, while those from individuals without
HIV showed a low polymorphism [16,56,57]. These dif-
ferences might be useful for the differentiation and clas-
sification of strains that can only infect HIV patients.
Some authors have found that MIRU-VNTR based on a
12-loci set (MIRU-12) format have limitations in its dis-
criminatory power [58-60]. Recently, two MIRU-VNTR
formats (MIRU-15 and MIRU-24) have been developed
to improve the discriminatory power of MIRU-12 [61],
and found a better discriminatory power using the set of
15-loci (MIRU-15) with 825 MTb isolates. However, in
our study, the MIRU-12 allowed us to demonstrate a
high genetic diversity in mycobacterial strains belonging
to the MTC; in order to get a more definitive answer to
this matter, more genotyping analysis should be carried
out with MTb strains from different origins.
Since all isolates were collected from HIV-infected
patients, we suggest to analyze MTC strains from non
VIH-infected patients from the same region in order to
enhance the significance of our results.
MDR TB is an increasing problem worldwide [62].
Infection with MDR MTb is associated with significant
mortality [18], and has resulted in a number of serious
outbreaks [63]. Colorimetric microplate Alamar Blue
assay (MABA) assays demonstrated that all isolated
M. bovis strains were susceptible to the antibiotics tested.
On the other hand, 19 (39.6%) isolated MTb strains were
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very close to those obtained by Peter et al [64], who
demonstrated that 41% of the MTb strains isolated from
patients from Baja California (Mexico) were resistant to
at least one antibiotic. Our study showed that 2.1% of the
strains we identified were MDR, confirming the inci-
dence of MDR TB in Mexico already reported by the
WHO [4]. The highest proportions of strains were resis-
tant to STR, as has also been reported to be the case in
Africa for both HIV-infected and patients without HIV
[65,66]. Due to the importance of INH and RIF, which
are the most effective antibiotics against TB, we deter-
mined the mutations that lead to the selection of resis-
tant strains in our study. Three INH-resistant strains
showed a mutation AGC ® ACC (Ser ® Thr) at codon
315 of katG gene, a finding consistent with several stu-
dies, which have shown that this mutation is the most
frequently associated with this resistance [27,67]. In our
country, this mutation seems to be as frequent [27,28], as
in other countries such as Russia and Brazil [20,67]. In
this study, no correlation was found between genotypic
drug resistance and genotypic patterns, findings which
were consistent with those previously reported for MTb
strains isolated in both HIV-infected and non HIV-
infected patients [27,66,67]. On the other hand, one RIF-
resistant isolate had a mutation GAG ® TCG (Glu ®
Ser) at codon 469 of rpoB gene, which has not been pre-
viously described, and which should be the object for
further study of other strains in Mexico.
Conclusions
This is the first molecular analysis of mycobacteria iso-
l a t e df r o mH I V - i n f e c t e dp a t i e n t si nM e x i c o ,w h i c h
describe the prevalence of different mycobacterial spe-
cies in this population. Using a combination of different
molecular techniques a high genetic diversity of MTb
strains was identified. New spoligotypes and MIRU-
VNTR patterns as well as a novel mutation associated
to RIF-resistance were found. This information will
facilitate the tracking of different mycobacterial species
in HIV-infected individuals, and monitoring the spread
of these microorganisms, leading to more appropriate
measures for TB control in these patients.
Methods
The present experimental research that is reported in
the manuscript has been performed with the approval of
the Ethical Committee of the Escuela Nacional de Cien-
cias Biologicas, IPN, Mexico and carried out within an
ethical framework.
Mycobacterial strains
Sixty seven Mycobacterial strains were isolated from 55
HIV-infected patients at different National Health
Service hospitals in Mexico City (General Hospital of
Mexico, Hospital Regional “General Ignacio Zaragoza”,
National Medical Center “Siglo XXI” and National Med-
ical Center “La Raza”) between January and December
2006. All patients were on treatment with antiretroviral
medication and their CD4 lymphocyte counts varied
from 100 to 300 cells/mm
3. According the WHO data
[68], the 55 HIV/TB patients corresponded aprox. to
21% of the total patients attended in México in 2006.
Mycobateria were isolated from sputum, bronchoal-
veolar lavage fluid, cerebrospinal fluid, urine, bone mar-
row, lymph node, pleural effusion, ascitic fluid, tissue
biopsy, pericardial fluid, gastric fluid. Isolation and iden-
tification of mycobacteria was carried out by the Micro-
biology service of each hospital using acid-fast staining
(AFB).
Thirty-one (46.3%) strains were isolated from sputum
and 36 (53.7%) from extrapulmonary clinical samples.
Identification of mycobacterial species
Mycobacterial genomic DNA was isolated by guanidi-
nium chloride extraction [69]. The identity of the 67
isolated strains was confirmed by PCR as described pre-
viously [70]. Briefly, a multiplex PCR reaction was per-
formed to identify the genus of Mycobacterium and M.
bovis species, and a second PCR reaction was carried
out to determine if a clinical isolate belonged to the M.
tuberculosis complex. Nontuberculous mycobacteria
(NTM) were identified by sequencing the V2 region of
the 16S rRNA gene [71], using the RAC8 primer (5’-
CACTGGTGCCTCCCGTAGG-3’), and ABI PRISM 310
genetic analyzer (Perkin-Elmer). All sequences were ana-
lyzed by BLAST [72].
DNA fingerprinting
Mycobacterial strains belonging to MTC were subjected
to spoligotyping, MIRU-VNTR analysis, phenotypic and
genotypic drug resistance tests. Only MTb strains were
subsequently subjected to restriction fragment length
polymorphism (RFLP) analysis.
IS6110 RFLP
IS6110 fingerprinting was performed as described pre-
viously [73]. Briefly, genomic DNA from each MTb iso-
late (2 μg) was digested with PvuII. Fragments were
separated by electrophoresis on agarose gels, denatured
and transferred by Southern blotting to nylon mem-
brane. Hybridization was performed with a chemilumi-
nescence-labeled 521-bp IS6110 fragment. MTb H37Rv
was used as control.
Spoligotyping
This technique was carried out as described previously
[11]. The DR region was amplified using oligonucleotides
DRa (5’-GGTTTTGGGTCTGACGAC-3’, biotinylated)
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amplification products were used as a probe for hybridi-
zation with 43 synthetic spacer oligonucleotides cova-
lently bound to a membrane (Isogen Biosciences B.M.,
Maarssen, The Netherlands). Each oligonucleotide corre-
sponded to a known spacer sequence. PCR product
bound after hybridization was detected by streptavidin-
horseradish peroxidase-enhanced chemiluminescence
(Amersham, Little Chalfont, England) according to man-
ufacturer’s instructions. Spoligotypes were reported using
an octal code [74]. Analysis of spoligotypes was per-
formed using Bionumerics software version 5.5 (Applied
Maths, Kortrijk, Belgium). MTb H37Rv and M. bovis
BCG were used as controls.
MIRU-VNTR analysis
MIRU-VNTR typing was performed as described pre-
viously [16]. Bacteria were resuspended in 200 μl milli-
Q water, boiled for 10 min, and cooled on ice or 5 min.
Supernatant from bacterial lysates (2 μl) was added to
MIRU-PCR mix (0.1 μlo fH o t S t a r tTaq DNA polymer-
ase (0.5 U) (Qiagen) with 4 μlo fQ - s o l u t i o n ,0 . 5m M
each dATP, dCTP, dGTP, dTTP, 2 μlo fP C Rb u f f e r ,
variable concentrations of each primer, and 1.5 mM
MgCl2)i n2 0μl final volume. The oligonucleotides used
corresponded to the flanking regions of the 12 poly-
morphic MIRU-VNTR loci identified in the M. tubercu-
losis H37Rv genome as described by Supply et al [75].
PCR reactions were performed in a PXE0.2 thermo
cycler (Thermo Electron Corporation) following a proto-
col of: 95°C for 15 min, followed by 40 cycles of 94°C
f o r1m i n ,5 9 ° Cf o r1m i n ,a n d7 2 ° Cf o r1 . 5m i n ,w i t ha
final extension at 72°C for 10 min. PCR fragments were
analyzed on a 2100 Bioanalyser (Agilent Technologies).
Genotypes were expressed as numerical code represent-
ing the number of MIRU-VNTR in each loci. A dendro-
gram was constructed by the unweighted-pair group
method using average linkages (UPGMA) after pairwise
comparison of strains by calculation of the Jaccard
index.
Phenotypic drug resistance testing (PDRT)
Strains were tested for PDR by colorimetric microplate
Alamar Blue assay (MABA) in 96-well flat-bottom plates
(Nunc International, Rochester, NY, USA) as described
by Franzblau et al [76], with some modifications [77].
Briefly, cultures in exponential growth phase were
diluted with sterile Middlebrook 7H9 broth supplemen-
ted with 10% OADC (oleate-albumin-dextrose-catalase)
until they reached McFarland tube no. 1 turbidity, then
further diluted 1:10. Streptomycin (STR), isoniazid
(INH), ethambutol (EMB) and rifampin (RIF) were
obtained from Sigma Chemical (USA). One hundred
microliters of MTb inoculum was incubated in medium
without drug or with drugs in the following concentra-
t i o nr a n g e s :I N H ,1t o0 . 0 3 1μg / m l ;R I F ,2t o0 . 0 6 2μg/
ml; STR, 8 to 0.25 μg/ml; and EMB, 32 to 1 μg/ml. Fol-
lowing incubation for 5 days at 37°C indicator solution
(20 μl of Alamar Blue [Trek, OH, USA] and 12 μlo f
sterile 10% Tween 80) was added to control inoculi
without drugs and plates were incubated at 37°C for a
further 24 h. If the medium in control inoculi turned
pink, subsequently indicator solution was added to
inoculi that had been incubated with drugs and after 24
h incubation the colour of all the samples was recorded.
Wells remaining blue were scored as “negative growth”.
The minimal inhibitory concentration (MIC) was
defined as the lowest drug concentration that prevented
colour change. If by day 6 no change was recorded in
the drug-free control, the plate was incubated for a
further 3 days; if control inoculi were still negative, a
second control inoculum was used (day 9) and the
whole procedure was repeated. MTb H37Rv was
included as control strain. An isolate was considered
drug resistant when the MIC was higher than 0.25 μg/
ml for INH, 0.25 μg/ml for RIF, 2.0 μg/ml for STR, and
8 μg/ml for EMB [77]. Multidrug resistance (MDR) was
defined in accordance with standard criteria of resis-
tance to both INH and RIF at least.
Genotypic drug resistance testing
Multiplex PCR [78] was used to detect the AGC ®
ACC (serine to threonine) mutation in codon 315 of the
katG gene (primers: katg0F 5’-GCAGATGGGGCT-
GATCTACG-3’ and R315 mut 5’-TCCATACGACCTC-
GATGCCAG-3’) and to detect -15 C-to-T and -14
G-to-A substitutions (primers: mabAF 5’-CGAAGTGT-
GCTGAGTCACACCG-3’ and inhARmut 5’-AGT-
CACCCCGACAACCTATTA-3’) within the promoter
region of the mabA-inhA operon. Following PCR, DNA
from resistant strains with these mutations yielded 296-
bp and/or 146-bp PCR products. Bacterial DNA (50-100
ng) was used as a template in PCR reactions with pure-
Taq Ready-To-Go PCR bead kit (Amersham Bios-
ciences, Piscataway, N.J.). The PCR mix consisted of 10
mM Tris-HCl (pH 9), 50 mM KCl, 1.5 mM MgCl2,a
200 μM of each deoxynucleotide, 2.5 U of pureTaq
DNA polymerase and PCR primers (200 mM for katG
and 400 mM for mabA-inhA) in a final volume of 25 μl.
Reactions were performed in a PXE0.2 thermo cycler
(Thermo Electron Corporation) starting with a 5 min
denaturation at 95°C, followed by 30 cycles of 95°C for
1 min, 68°C for 1 min and 72°C for 45 s, with a final
extension at 72°C for 10 min. PCR products were
resolved by electrophoresis in 2% agarose gels and
detected by staining with ethidium bromide.
Rifampin resistant isolates were detected by
amplification of a 437 bp fragment incorporating the
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Page 9 of 12rpoB-hotspot region from bacterial DNA using primers
rpoB-F1 and rpoB-R1 as described previously [25]. PCR
products were sequenced using a 310 ABI PRISM
sequencer (Applied Biosystems). Sequences were com-
pared to the sequence of the rpoB-hotspot from wild-
type bacteria using BLAST [72].
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